MedTrace Logo

Prescription Opioid Effects in Abusers Versus Non-Abusers

NCT00158184 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2017-07-07

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to examine the abuse liability of oxycodone in individuals with, and without, a history of prescription opioid abuse.

Conditions

  • Opioid-Related Disorders
  • Substance-Related Disorders

Interventions

DRUG

oxycodone 15 mg

15 mg/70 kg oxycodone administered once per day, orally.

DRUG

oxycodone 30 mg

30 mg/70 kg oxycodone administered once per day, orally.

DRUG

Placebo 0 mg

0 mg placebo dose administered once a day, orally.

Sponsors & Collaborators

  • National Institute on Drug Abuse (NIDA)

    collaborator NIH

  • New York State Psychiatric Institute

    lead OTHER

Principal Investigators

  • Sandra Comer, PhD · New York State Psychiatric Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2004-06-30
Primary Completion
2009-06-30
Completion
2009-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00158184 on ClinicalTrials.gov